Hikma buys Boehringer injectable drugs business for up to $300 mln
May 28, 2014 at 07:26 AM EDT
LONDON, May 28 (Reuters) - Hikma Pharmaceuticals said on Wednesday it had agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.
